Literature DB >> 2822887

Nephrocalcinosis and its relationship to treatment of hereditary rickets.

P R Goodyer1, J B Kronick, S Jequier, T M Reade, C R Scriver.   

Abstract

Renal ultrasonography was performed on 23 patients with X-linked hypophosphatemic rickets (XLH) and 11 patients with autosomal recessive vitamin D-dependent rickets (ARVDD). A pattern of increased echogenicity of the renal pyramids (ERP) was identified in 11/23 patients with XLH and 3/11 patients with ARVDD; this ultrasonographic finding has previously been associated with medullary nephrocalcinosis. Patients with XLH and ERP had significantly higher mean serum calcium and phosphate concentrations, more frequent episodes of hypercalcemia, and higher doses of oral vitamin D and phosphate during the first 3 years of therapy. Episodes of hypercalcemia were more frequent when patients received higher doses of vitamin D2 (greater than 4000 IU/kg/day) or 1,25-dihydroxycholecalciferol (greater than 40 ng/kg/day). Episodes of hypercalciuria were significantly increased at doses of greater than 20 ng/kg/day 1,25-dihydroxycholecalciferol. In patients with ARVDD, ERP was also correlated with vitamin D dose and frequency of hypercalcemia episodes. ERP was not associated with an elevation of serum creatinine or loss of urinary concentrating ability in either patient group.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2822887     DOI: 10.1016/s0022-3476(87)80245-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  18 in total

1.  X linked hypophosphataemia: treatment, height gain, and nephrocalcinosis.

Authors:  G S Reusz; P F Hoyer; M Lucas; H P Krohn; J H Ehrich; J Brodehl
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

Review 2.  Role of prostaglandins in the pathogenesis of X-linked hypophosphatemia.

Authors:  Michel Baum; Ashu Syal; Raymond Quigley; Mouin Seikaly
Journal:  Pediatr Nephrol       Date:  2006-05-24       Impact factor: 3.714

3.  Hypophosphatemic rickets: results of a long-term follow-up.

Authors:  Maria Helena Vaisbich; Vera H Koch
Journal:  Pediatr Nephrol       Date:  2005-10-27       Impact factor: 3.714

Review 4.  X-linked hypophosphatemia and growth.

Authors:  R Fuente; H Gil-Peña; D Claramunt-Taberner; O Hernández; A Fernández-Iglesias; L Alonso-Durán; E Rodríguez-Rubio; F Santos
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

5.  Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment.

Authors:  Catherine Quinlan; Katie Guegan; Amaka Offiah; Richard O' Neill; Melanie P Hiorns; Sian Ellard; Detlef Bockenhauer; William Van't Hoff; Aoife M Waters
Journal:  Pediatr Nephrol       Date:  2011-11-20       Impact factor: 3.714

6.  Causes of increased renal medullary echogenicity in Turkish children.

Authors:  A Nayir; A Kadioğlu; A Sirin; S Emre; E Tonguç; I Bilge
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

Review 7.  FGF23 and Associated Disorders of Phosphate Wasting.

Authors:  Anisha Gohil; Erik A Imel
Journal:  Pediatr Endocrinol Rev       Date:  2019-09

8.  Hypertension in hypophosphatemic rickets--role of secondary hyperparathyroidism.

Authors:  Uri S Alon; Roshanak Monzavi; Marc Lilien; Majid Rasoulpour; Mitchell E Geffner; Ora Yadin
Journal:  Pediatr Nephrol       Date:  2003-01-18       Impact factor: 3.714

9.  Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus disease.

Authors:  A Taylor; N H Sherman; M E Norman
Journal:  Pediatr Nephrol       Date:  1995-04       Impact factor: 3.714

Review 10.  Therapeutics of X-linked hypophosphatemic rickets.

Authors:  K Latta; S Hisano; J C Chan
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.